Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

MCTA vs CANG

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
MCTA
Charming Medical Limited Class A Ordinary Shares

Medical - Care Facilities

HealthcareNASDAQ • HK
Market Cap$445M
5Y Perf.+33.2%
CANG
Cango Inc.

Auto - Dealerships

Consumer CyclicalNYSE • CN
Market Cap$250M
5Y Perf.-28.7%

MCTA vs CANG — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
MCTA logoMCTA
CANG logoCANG
IndustryMedical - Care FacilitiesAuto - Dealerships
Market Cap$445M$250M
Revenue (TTM)$6M$3.46B
Net Income (TTM)$1M$-178M
Gross Margin67.2%13.6%
Operating Margin22.3%7.3%
Forward P/E414.5x5.7x
Total Debt$1M$170M
Cash & Equiv.$817K$1.29B

Quick Verdict: MCTA vs CANG

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MCTA leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Cango Inc. is the stronger pick specifically for valuation and capital efficiency and capital preservation and lower volatility. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
MCTA
Charming Medical Limited Class A Ordinary Shares
The Growth Play

MCTA carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 3.4%, EPS growth 54.2%
  • 319.3% 10Y total return vs CANG's -44.9%
  • 3.4% revenue growth vs CANG's -52.7%
Best for: growth exposure and long-term compounding
CANG
Cango Inc.
The Defensive Pick

CANG is the clearest fit if your priority is sleep-well-at-night and defensive.

  • Lower volatility, beta 2.25, Low D/E 4.1%, current ratio 1.88x
  • Beta 2.25, current ratio 1.88x
  • Lower P/E (5.7x vs 414.5x)
Best for: sleep-well-at-night and defensive
See the full category breakdown
CategoryWinnerWhy
GrowthMCTA logoMCTA3.4% revenue growth vs CANG's -52.7%
ValueCANG logoCANGLower P/E (5.7x vs 414.5x)
Quality / MarginsMCTA logoMCTA19.3% margin vs CANG's -5.2%
Stability / SafetyCANG logoCANGLower D/E ratio (4.1% vs 23.6%)
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)MCTA logoMCTA+319.3% vs CANG's -73.7%
Efficiency (ROA)MCTA logoMCTA23.4% ROA vs CANG's -2.3%, ROIC 265.0% vs 4.6%

MCTA vs CANG — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

MCTACharming Medical Limited Class A Ordinary Shares

Segment breakdown not available.

CANGCango Inc.
FY 2024
After-market Service Facilitation Service Income
62.9%$41M
Loan Facilitation Income And Other Related Income
24.1%$16M
Automobile trading income
9.6%$6M
Service, Other
3.4%$2M

MCTA vs CANG — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMCTALAGGINGCANG

Income & Cash Flow (Last 12 Months)

MCTA leads this category, winning 4 of 4 comparable metrics.

CANG is the larger business by revenue, generating $3.5B annually — 556.1x MCTA's $6M. MCTA is the more profitable business, keeping 19.3% of every revenue dollar as net income compared to CANG's -5.2%.

MetricMCTA logoMCTACharming Medical …CANG logoCANGCango Inc.
RevenueTrailing 12 months$6M$3.5B
EBITDAEarnings before interest/tax$333M
Net IncomeAfter-tax profit-$178M
Free Cash FlowCash after capex$0
Gross MarginGross profit ÷ Revenue+67.2%+13.6%
Operating MarginEBIT ÷ Revenue+22.3%+7.3%
Net MarginNet income ÷ Revenue+19.3%-5.2%
FCF MarginFCF ÷ Revenue+2.2%-154.0%
Rev. Growth (YoY)Latest quarter vs prior year+58.3%
EPS Growth (YoY)Latest quarter vs prior year+3.6%
MCTA leads this category, winning 4 of 4 comparable metrics.

Valuation Metrics

CANG leads this category, winning 4 of 4 comparable metrics.

At 5.7x trailing earnings, CANG trades at a 99% valuation discount to MCTA's 414.5x P/E. On an enterprise value basis, CANG's 3.1x EV/EBITDA is more attractive than MCTA's 269.8x.

MetricMCTA logoMCTACharming Medical …CANG logoCANGCango Inc.
Market CapShares × price$445M$250M
Enterprise ValueMkt cap + debt − cash$446M$85M
Trailing P/EPrice ÷ TTM EPS414.55x5.66x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple269.80x3.13x
Price / SalesMarket cap ÷ Revenue71.60x2.12x
Price / BookPrice ÷ Book value/share9999.00x0.42x
Price / FCFMarket cap ÷ FCF3219.65x
CANG leads this category, winning 4 of 4 comparable metrics.

Profitability & Efficiency

MCTA leads this category, winning 7 of 9 comparable metrics.

MCTA delivers a 24.4% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-4 for CANG. CANG carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to MCTA's 23.57x. On the Piotroski fundamental quality scale (0–9), MCTA scores 6/9 vs CANG's 4/9, reflecting solid financial health.

MetricMCTA logoMCTACharming Medical …CANG logoCANGCango Inc.
ROE (TTM)Return on equity+24.4%-4.1%
ROA (TTM)Return on assets+23.4%-2.3%
ROICReturn on invested capital+2.6%+4.6%
ROCEReturn on capital employed+3.4%+4.5%
Piotroski ScoreFundamental quality 0–964
Debt / EquityFinancial leverage23.57x0.04x
Net DebtTotal debt minus cash$343,868-$1.1B
Cash & Equiv.Liquid assets$816,771$1.3B
Total DebtShort + long-term debt$1M$170M
Interest CoverageEBIT ÷ Interest expense66.54x-1.87x
MCTA leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

MCTA leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in MCTA five years ago would be worth $41,929 today (with dividends reinvested), compared to $8,579 for CANG. Over the past 12 months, MCTA leads with a +319.3% total return vs CANG's -73.7%. The 3-year compound annual growth rate (CAGR) favors MCTA at 61.3% vs CANG's 0.4% — a key indicator of consistent wealth creation.

MetricMCTA logoMCTACharming Medical …CANG logoCANGCango Inc.
YTD ReturnYear-to-date-0.0%-62.0%
1-Year ReturnPast 12 months+319.3%-73.7%
3-Year ReturnCumulative with dividends+319.3%+1.2%
5-Year ReturnCumulative with dividends+319.3%-14.2%
10-Year ReturnCumulative with dividends+319.3%-44.9%
CAGR (3Y)Annualised 3-year return+61.3%+0.4%
MCTA leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

MCTA leads this category, winning 1 of 1 comparable metric.

MCTA currently trades 92.6% from its 52-week high vs CANG's 18.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricMCTA logoMCTACharming Medical …CANG logoCANGCango Inc.
Beta (5Y)Sensitivity to S&P 5002.25x
52-Week HighHighest price in past year$31.70$2.88
52-Week LowLowest price in past year$4.30$0.33
% of 52W HighCurrent price vs 52-week peak+92.6%+18.6%
RSI (14)Momentum oscillator 0–10078.558.6
Avg Volume (50D)Average daily shares traded01.3M
MCTA leads this category, winning 1 of 1 comparable metric.

Analyst Outlook

Insufficient data to determine a leader in this category.
MetricMCTA logoMCTACharming Medical …CANG logoCANGCango Inc.
Analyst RatingConsensus buy/hold/sellBuy
Price TargetConsensus 12-month target$3.00
# AnalystsCovering analysts2
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises5
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%+5.3%
Insufficient data to determine a leader in this category.
Key Takeaway

MCTA leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CANG leads in 1 (Valuation Metrics).

Best OverallCharming Medical Limited Cl… (MCTA)Leads 4 of 6 categories
Loading custom metrics...

MCTA vs CANG: Frequently Asked Questions

9 questions · data-driven answers · updated daily

01

Is MCTA or CANG a better buy right now?

For growth investors, Charming Medical Limited Class A Ordinary Shares (MCTA) is the stronger pick with 3.

4% revenue growth year-over-year, versus -52. 7% for Cango Inc. (CANG). Cango Inc. (CANG) offers the better valuation at 5. 7x trailing P/E, making it the more compelling value choice. Analysts rate Cango Inc. (CANG) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — MCTA or CANG?

On trailing P/E, Cango Inc.

(CANG) is the cheapest at 5. 7x versus Charming Medical Limited Class A Ordinary Shares at 414. 5x.

03

Which is the better long-term investment — MCTA or CANG?

Over the past 5 years, Charming Medical Limited Class A Ordinary Shares (MCTA) delivered a total return of +319.

3%, compared to -14. 2% for Cango Inc. (CANG). Over 10 years, the gap is even starker: MCTA returned +319. 3% versus CANG's -44. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — MCTA or CANG?

On balance sheet safety, Cango Inc.

(CANG) carries a lower debt/equity ratio of 4% versus 24% for Charming Medical Limited Class A Ordinary Shares — giving it more financial flexibility in a downturn.

05

Which is growing faster — MCTA or CANG?

By revenue growth (latest reported year), Charming Medical Limited Class A Ordinary Shares (MCTA) is pulling ahead at 3.

4% versus -52. 7% for Cango Inc. (CANG). On earnings-per-share growth, the picture is similar: Cango Inc. grew EPS 960. 0% year-over-year, compared to 54. 2% for Charming Medical Limited Class A Ordinary Shares. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — MCTA or CANG?

Cango Inc.

(CANG) is the more profitable company, earning 37. 3% net margin versus 19. 3% for Charming Medical Limited Class A Ordinary Shares — meaning it keeps 37. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MCTA leads at 22. 3% versus 22. 2% for CANG. At the gross margin level — before operating expenses — MCTA leads at 67. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Which pays a better dividend — MCTA or CANG?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

08

Is MCTA or CANG better for a retirement portfolio?

For long-horizon retirement investors, Charming Medical Limited Class A Ordinary Shares (MCTA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+319.

3% 10Y return). Cango Inc. (CANG) carries a higher beta of 2. 25 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MCTA: +319. 3%, CANG: -44. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between MCTA and CANG?

These companies operate in different sectors (MCTA (Healthcare) and CANG (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MCTA is a small-cap quality compounder stock; CANG is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

MCTA

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 11%
Run This Screen
Stocks Like

CANG

High-Growth Disruptor

  • Sector: Consumer Cyclical
  • Market Cap > $100B
  • Revenue Growth > 2916%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform MCTA and CANG on the metrics below

Revenue Growth>
%
(MCTA: 3.4% · CANG: 5833.4%)
P/E Ratio<
x
(MCTA: 414.5x · CANG: 5.7x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.